-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, B0xVQa77qNxS7PIpnpyFDyh7J1IMD1aA20hTFC7+jmufTrEYqXWj0iwddYcaKSbr 57tdOcO1Lr0sY96xdFcx2w== 0000950136-04-002201.txt : 20040712 0000950136-04-002201.hdr.sgml : 20040712 20040712162649 ACCESSION NUMBER: 0000950136-04-002201 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20040712 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: NEXMED INC CENTRAL INDEX KEY: 0001017491 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 870449967 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-53409 FILM NUMBER: 04910423 BUSINESS ADDRESS: STREET 1: 350 CORPORATE BLVD CITY: ROBBINSVILLE STATE: NJ ZIP: 08691 BUSINESS PHONE: 6092089688 MAIL ADDRESS: STREET 1: 350 CORPORATE BLVD CITY: ROBBINSVILLE STATE: NJ ZIP: 08691 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: MO Y JOSEPH CENTRAL INDEX KEY: 0001055374 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 870449967 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: 350 CORPORATE BLVD STREET 2: C/O NEXMED INC CITY: ROBBINSVILLE STATE: NJ ZIP: 08691 BUSINESS PHONE: 6092089688 MAIL ADDRESS: STREET 1: 350 CORPORATE BLVD STREET 2: C/O NEXMED INC CITY: ROBBINSVILLE STATE: NJ ZIP: 08691 SC 13D/A 1 file001.txt AMENDMENT NO. 2 TO SCHEDULE 13D SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13D-1) (AMENDMENT NO. 2)* INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13D-1(A) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13D-2(A) NexMed, Inc. ---------------------- (Name of Issuer) Common Stock, $0.001 Par Value ----------------------------------------- (Title of Class of Securities) 652903105 ----------- (CUSIP Number) Y. Joseph Mo, Ph. D. NexMed, Inc. 350 Corporate Boulevard Robbinsville, NJ 08691 - -------------------------------------------------------------------------------- (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) July 12, 2004 (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of ss.ss. 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. [ ] The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). (Continued on following pages) Page 1 of 4
-------------------------------------------------- ------------------------ CUSIP NO. 652903105 Page 2 of 4 -------------------------------------------------- ------------------------ - --------- ----------------------------------------------------------------------------------------------------- 1 NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Y. JOSEPH MO, PH.D - --------- ----------------------------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [ ] - --------- ----------------------------------------------------------------------------------------------------- 3 SEC USE ONLY - --------- ----------------------------------------------------------------------------------------------------- 4 SOURCE OF FUNDS (SEE INSTRUCTIONS) N/A - --------- ----------------------------------------------------------------------------------------------------- 5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED [ ] PURSUANT TO ITEMS 2(d) or (e) - --------- ----------------------------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION UNITED STATES OF AMERICA - ----------------------------- ---------------- ---------------------------------------------------------------- NUMBER OF 7 SOLE VOTING POWER SHARES 4,074,000 BENEFICIALLY ---------------- ---------------------------------------------------------------- OWNED BY EACH 8 SHARED VOTING POWER REPORTING 0 PERSON ---------------- ---------------------------------------------------------------- WITH 9 SOLE DISPOSITIVE POWER 4,074,000 ---------------- ---------------------------------------------------------------- 10 SHARED DISPOSITIVE POWER 0 - --------- ----------------------------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 4,074,000 - --------- ----------------------------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES.* [ ] - --------- ----------------------------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 8.4% - --------- ----------------------------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IN - ---------------------------------------------------------------------------------------------------------------
Page 2 of 4 Item 1. Security and Issuer This Amendment No. 2 amends and supplements the Schedule 13D originally filed with the Securities and Exchange Commission (the "SEC") on July 11, 2002 (the "Schedule 13D"), as amended by Amendment No. 1 to the Schedule 13D filed with the SEC on January 10, 2003, by the undersigned relating to the shares of common stock, par value $0.001 per share (the "Common Stock") of NexMed, Inc. (the "Issuer"), a Nevada corporation. The Issuer's principal executive offices are located at 350 Corporate Boulevard, Robbinsville, NJ 08691. Item 3. Source and Amount of Funds or Other Consideration Item 3 of the Schedule 13D is hereby amended and restated in its entirety as follows: As of July 12, 2004, the Reporting Person beneficially owned 4,074,000 shares of Common Stock, consisting of (i) 1,000,000 shares granted by the Issuer on February 16, 1996 for services rendered; (ii) 100,000 shares acquired on April 9, 1998 upon the exercise of non-qualified stock options with an exercise price of $.25 per share; (iii) 400,000 shares acquired on January 11, 2000 upon the exercise of non-qualified stock options with an exercise price of $.25 per share; (iv) 10,000 shares acquired on May 20, 2003 upon the exercise of non-qualified stock options with an exercise price of $0.81 per share; (v) 100,000 shares granted by the Issuer on July 6, 2004 as the Reporting Person's bonus for 2003; and (vi) 2,464,000 shares underlying options which are exercisable within the next 60 days. The source of funds for the exercise prices for the Reporting Person's exercised stock options were the private funds of the Reporting Person. Item 5. Interest in Securities of the Issuer Paragraphs (a) - (c) of Item 5 of the Schedule 13D are hereby amended and restated in their entireties as follows: (a) As of July 12, 2004 and based upon a total of 45,956,781 shares of Common Stock outstanding as of such date, the Reporting Person beneficially owns 4,074,000 shares of Common Stock, representing approximately 8.4% of the Issuer's outstanding Common Stock comprised of: (i) 1,410,000 shares owned directly by the Reporting Person; (ii) 200,000 shares held by a retained annuity trust for the benefit of the Reporting Person, of which he is the sole trustee; and (iii) 2,464,000 shares of Common Stock which the Reporting Person has the right to acquire upon the exercise of options within the next 60 days. (b) The Reporting Person has the sole power to vote and dispose of the 4,074,000 shares beneficially owned by him. (c) The following transaction increased the Reporting Person's beneficial ownership within the past 60 days: On July 12, 2004, the Reporting Person received his bonus for 2003 of 100,000 shares of the Company's Common Stock. Such shares were to be issued within ten days following the later of the delivery of the Company's audited financial statements for 2003 or the signing of an agreement for one of its products under development. On July 6, 2004, the Company entered into such an agreement. Page 3 of 4 Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: July 12, 2004 /s/ Y. Joseph Mo ---------------- Y. Joseph Mo Page 4 of 4 -----END PRIVACY-ENHANCED MESSAGE-----